First-line Treatment of VR-CAP Regimen Shows Efficacy in Marginal Zone Lymphoma
October 23rd 2023In a phase 2 study, frontline bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, and cytarabine hydrochloride was well tolerated in patients with B-cell non-Hodgkin marginal zone lymphoma.
Read More
First-Line Amivantamab Plus Lazertinib Represents New SOC in Advanced EGFR+ NSCLC
October 23rd 2023Amivantamab-vmjw with lazertinib showed positive survival results vs osimertinib as frontline therapy for patients with advanced non–small cell lung cancer harboring classical EGFR sensitizing mutations.
Read More
Lenvatinib/Pembrolizumab Plus Chemotherapy Shows Manageable Toxicity in mESCC
October 23rd 2023The safety run-in of the LEAP-014 trial showed acceptable toxicity and antitumor responses in patients with metastatic esophageal cancer receiving pembrolizumab, lenvatinib, and chemotherapy consisting of cisplatin plus either paclitaxel or 5-fluororacil.
Read More
Continued Benefit Shown With Pembrolizumab, Lenvatinib in Endometrial Cancer
October 23rd 2023An exploratory analysis of Study 309/KEYNOTE-775 showed further benefit for patients and consistent safety in patients who received pembrolizumab plus lenvatinib for advanced endometrial cancer who continued lenvatinib treatment.
Read More
Dato-DXd Induces Significantly Improved PFS in HR+, HER2- Metastatic Breast Cancer
October 23rd 2023Treatment with datopotamab deruxtecan led to a statistically significant and clinically meaningful improvement in progression-free survival in patients with metastatic hormone receptor-positive breast cancer.
Read More
Three of 4 Molecular Subgroups Respond to Dostarlimab in Advanced Endometrial Carcinoma
October 23rd 2023Findings from the ENGOT-EN6-NSGO/GOG-3031/RUBY trial showed that patients with dMMR/MSI-H had a progression-free survival rate of 57.0% in the dostarlimab arm vs 10.2% in the placebo arm.
Read More
PFS Improvement Seen With Cabozantinib in Previously Treated Advanced Neuroendocrine Tumors
October 23rd 2023At a median follow-up of 13.9 months, patients with extra-pancreatic NETs treated with cabozantinib experienced a median progression-free survival of 8.3 months vs 3.2 months with placebo.
Read More
Induction Chemotherapy Before Chemoradiation Betters Survival in Locally Advanced Cervical Cancer
October 23rd 2023Data presented at the 2023 ESMO Congress and showed that induction chemotherapy followed by chemoradiation reduced the risk of progression or death by 35% vs chemoradiation alone in patients with cervical cancer.
Read More
Survival Improved With Nivolumab Plus Chemo in Urothelial Carcinoma
October 22nd 2023The addition of nivolumab to frontline standard of care gemcitabine-cisplatin, followed by nivolumab maintenance therapy, led to statistically significant and clinically meaningful improvements in survival compared with gemcitabine-cisplatin alone in patients with unresectable or metastatic urothelial carcinoma.
Read More
Survival Benefit Shown With Niraparib Plus Abiraterone in BRCA+ mCRPC
October 22nd 2023Adding niraparib to abiraterone acetate and prednisone was associated with an overall survival benefit compared with AAP alone in patients with BRCA1/2-mutated metastatic castration-resistant prostate cancer.
Read More
Enfortumab Vedotin/Pembrolizumab Shows Encouraging Survival Data in mUC
October 22nd 2023Thomas Powles, MD, MBBS, MRCP, discusses findings from the phase 3 EV-302 clinical trial of enfortumab vedotin-ejfv with pembrolizumab vs chemotherapy for the treatment of patients with previously untreated locally advanced or metastatic urothelial cancer.
Watch
Selpercatinib Shows Superior Efficacy Vs Multikinase Inhibitors in Advanced RET+ MTC
October 21st 2023A trial comparing selpercatinib with cabozantinib or vandetanib led to greater benefit and favorable safety in the selpercatinib arm, supporting use of the selective RET inhibitor as first-line treatment for patients with advanced RET-mutant medullary thyroid cancer, according to interim data presented at the 2023 ESMO Congress.
Read More
EGFR Exon 20-Insertion NSCLC Population Sees PFS Benefit from Amivantamab/Chemotherapy
October 21st 2023Combining amivantamab, carboplatin, and pemetrexed in patients with non–small cell lung cancer and an EGFR exon 20 insertion led to improved progression-free survival, overall response rate, duration of response, and a trend toward overall survival benefit vs chemotherapy alone in the randomized phase 3 PAPILLON study.
Read More
Selpercatinib Improves Survival vs Chemotherapy in RET+ NSCLC
October 21st 2023Results phase 3 LIBRETTO-431 trial presented at the 2023 ESMO Congress showed selpercatinib monotherapy demonstrated better survival results than chemotherapy with or without pembrolizumab for patients with RET fusion–positive non–small cell lung cancer.
Read More
In ALK+ NSCLC Alectinib Reduces Disease Risks in Early-Stage Setting
October 21st 2023Results from the phase 3 ALINA trial showed the benefit of ALK inhibition for patients with ALK-positive, early-stage, non–small-cell lung cancer with use of adjuvant alectinib significantly improving disease-free survival.
Read More